Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX® NDA; no additional clinical data or device modifications required at this time.

Announced positive top-line results from the FREEDOM-HF study demonstrating that average 30-day heart failure-related costs were reduced by $17,753 per study subject in the FUROSCIX arm compared to historically matched comparators.

Ended Q2 with cash, cash equivalents, restricted cash and investments of $90.2 million, sufficient to fund operations, as currently planned, into 2023.

Lowered 2021 net loss guidance to $30.0 to $34.0 million.